ライフサイエンスコーパス: anaemia

1 asound findings in patients with sickle cell anaemia.

2 indices in the diagnosis of iron deficiency anaemia.

3 ating stroke risk in adults with sickle cell anaemia.

4 nd ineffective correction of iron-deficiency anaemia.

5 scular impairment in adults with sickle cell anaemia.

6 ication for haemoglobin less than 100 g/L or anaemia.

7 e the other two patients had weight loss and anaemia.

8 rd blood transfusion in children with severe anaemia.

9 ed donor transplantation for severe aplastic anaemia.

10 erited bone marrow failure syndrome, Fanconi anaemia.

11 leviates anaemia in a mouse model of chronic anaemia.

12 lower than 80 g/L or if they had symptoms of anaemia.

13 (-/-) mice from PHZ-induced acute haemolytic anaemia.

14 ed donor transplantation for severe aplastic anaemia.

15 nd iron-deficiency rather than megaloblastic anaemia.

16 1 patients assigned to six cycles had severe anaemia.

17 needed for chronic leg ulcers in sickle cell anaemia.

18 tic stem cell pool confers profound aplastic anaemia.

19 s Disease, Neurofibromatosis and Sickle Cell Anaemia.

20 the phenotypes seen in patients with Fanconi anaemia.

21 dren and achieve global targets for reducing anaemia.

22 y abnormalities in patients with sickle cell anaemia.

23 cers of autoantibodies that promote malarial anaemia.

24 , but with increased risk of severe malarial anaemia.

25 inability to estimate the cumulative risk of anaemia.

26 of corticosteroids in treating Epo-resistant anaemias.

27 se events that occurred through week 24 were anaemia (10 [5%]), cardiac failure (5 [2%]), pyrexia (4

28 mmon adverse events of grade 3 or worse were anaemia (11 [8%] of 132 patients in the gefitinib group

29 adverse events were neutropenia (13 [10%]), anaemia (11 [9%]), and pneumonia (six [5%]).

30 common grade 3 or worse adverse events were anaemia (14 [14%] of 104 in the momelotinib group vs sev

31 lycaemia (17 [22%] of 76 vs two [3%] of 78), anaemia (14 [18%] vs nine [12%]), neutropenia (13 [17%]

32 enia (21 [100%] patients for each toxicity); anaemia (14 [67%] patients); and infection (six [29%] pa

33 %]), leucopenia (13 [8%] vs nine [11%]), and anaemia (14 [8%] vs six [7%]).

34 up vs 21 [14%] of 150 in the control group), anaemia (14 [9%] vs 26 [17%]), and decreased neutrophil

35 e most common adverse events of grade 1 were anaemia (14 patients) and fatigue (13 patients), and the

36 18 [35%]), pneumonia (15 [29%] vs 19 [37%]), anaemia (15 [29%] vs 12 [23%]), and sepsis (eight [16%]

37 p), thrombocytopenia (21 [11%] vs 32 [16%]), anaemia (15 [8%] vs 20 [10%]) and infusion-related react

38 n both groups were haematological, including anaemia (150 [48%] of 313 patients in the doxorubicin pl

39 rse events were hypophosphataemia (19 [6%]), anaemia (17 [5%]), abdominal pain (13; 4%), and elevated

40 16 studies reported on management of anaemia, 17 on dialysis frequency, eight on dialysis acc

41 even patients]), and febrile neutropenia and anaemia (18% each [six patients]).

42 el (15; 5%), and in the nilotinib group were anaemia (18; 6%), elevated lipase level (15; 5%), elevat

43 eutropenia (43 [40%]), infection (21 [20%]), anaemia (19 [18%]), and thrombocytopenia (16 [15%]).

44 rtate aminotransferase levels (22 [5%]), and anaemia (19 [4%]).

45 rodysaesthesia syndrome (27 [8%] vs 3 [1%]), anaemia (19 [6%] vs 53 [17%]), hyperglycaemia (3 [1%] vs

46 he availability of pre-endoscopy serology in anaemia; 2) the sensitivities and cost effectiveness of

47 ]) compared with neutropenia (43 [39%]), and anaemia (20 [18%]), in the taxane group.

48 ir; and nasopharyngitis (40 [23.5%] of 170), anaemia (23 [13.5%] of 170), and headache in those recei

49 thrombocytopenia (23 [25%] of 93 patients), anaemia (23 [25%] of 93 patients), and sepsis (16 [17%]

50 rol patients: 26 (41%) versus nine (26%) had anaemia, 23 (36%) versus seven (21%) pyrexia, 22 (34%) v

51 ia (n=107 [43%]), leukopenia (53 [21%]), and anaemia (26 [10%]).

52 f 91 patients), thrombocytopenia (26 [29%]), anaemia (26 [29%]), decreased white blood cell count (17

53 s, 25%), neutropenia (30 patients, 16%), and anaemia (27 patients, 14%).

54 endoscopy coeliac screening with Simtomax in anaemia; 3) whether other anaemia-related pathologies co

55 eight [2%]), fatigue (39 [12%] vs 18 [5%]), anaemia (30 [9%] vs 34 [10%]), and abdominal pain (20 [6

56 common grade 3 or higher adverse events were anaemia (34 [18%] of 184 patients in the rigosertib grou

57 l tolerated; fatigue (42 [40%] patients) and anaemia (35 [33%]) of any grade were the most common adv

58 f 298 patients vs 97 [32%] of 299 patients), anaemia (37 [12%] vs 43 [14%]), and fatigue (30 [10%] vs

59 Common grade 3-4 adverse events included anaemia (37 [38%] of 97 patients) and thrombocytopenia (

60 atment, the most common grade 3 toxicity was anaemia (37 [47%]) and the most common grade 4 toxicity

61 rse events of grade 3 or worse severity were anaemia (38 [19%] of 195 patients in the olaparib group

62 ]), musculoskeletal pain (none vs ten [8%]), anaemia (39 [33%] vs six [5%]), and thrombocytopenia (38

63 acebo group), fatigue (40 [11%] vs 35 [9%]), anaemia (40 [10%] vs 43 [11%]), and colitis (18 [5%] vs

64 y were thrombocytopenia (43 [96%] patients), anaemia (41 [91%]), neutropenia (23 [51%]), diarrhoea (2

65 The prevalences of anaemia (42 [16%] vs 14 [11%], respectively) and rash (7

66 in grade 3/4 toxicities were haematological: anaemia (45%), thrombocytopenia (45%), and neutropenia (

67 [15%]), stomatitis (59 [13%] vs three [1%]), anaemia (46 [10%] vs six [3%]) and diarrhoea (43 [9%] vs

68 Common treatment-related toxic effects were anaemia (48 patients [48%]), nausea (42 [42%]), fatigue

69 and pneumonia (4 [2%]) with pacritinib, and anaemia (5 [5%]), sepsis (2 [2%]), and dyspnoea (2 [2%])

70 group), leucopenia (106 [38%] vs 82 [29%]), anaemia (53 [19%] vs 17 [6%]), febrile neutropenia (44 [

71 uzumab emtansine 2.4 mg/kg weekly group were anaemia (59 [26%]) and thrombocytopenia (25 [11%]) compa

72 (33-98), but at the expense of specificity (anaemia: 59% [35-79]; severe anaemia 90% [40-99]).

73 were febrile neutropenia (97 [39%] of 252), anaemia (61 [24%]), thrombocytopenia (33 [13%]), sepsis

74 ] of 175 patients), vomiting (63 [36%]), and anaemia (62 [35%]) in the chemotherapy group.

75 equent grade 3 or higher adverse events were anaemia (67 [14%] of 463 patients in the carfilzomib gro

76 openia (70 [22%] of 315 vs 61 [20%] of 312), anaemia (68 [22%] vs 49 [16%]), fatigue (23 [7%] vs 18 [

77 requent grade 3 or worse adverse events were anaemia (76 [16%] of 463 patients in the carfilzomib gro

78 febrile neutropenia (103 (46%) vs 30 [13%]), anaemia (78 [35%] vs 10 [5%]), and thrombocytopenia (75

79 uded multicentric lymphadenopathy (128/128), anaemia (79/91), elevated C-reactive protein (65/79), hy

80 [7%] vs 2 [2%]), infections (14 [7%] vs 0), anaemia (8 [4%] vs 1 [1%]), fatigue (7 [3%] vs 1 [1%]),

81 tivity (anaemia: 91% [95% CI 81-96]); severe anaemia 83% (33-98), but at the expense of specificity (

82 se events were diarrhoea (92 [37%] of 252]), anaemia (86 [34%]), fatigue (83 [33%]), elevated asparta

83 of specificity (anaemia: 59% [35-79]; severe anaemia 90% [40-99]).

84 the HCS could result in higher sensitivity (anaemia: 91% [95% CI 81-96]); severe anaemia 83% (33-98)

85 ents (aged </=65 years) with severe aplastic anaemia, adequate organ function, and an unrelated adult

86 Anaemia affects roughly a third of the world's populatio

87 For high-risk children with sickle cell anaemia and abnormal TCD velocities who have received at

88 her all the patients with chronic haemolytic anaemia and alcoholic cirrhosis had black pigment GS.

89 ole of the human RAD51 paralogues in Fanconi anaemia and cancer predisposition.

90 the chronic effects of sustained haemolytic anaemia and episodic vaso-occlusive events drive the dev

91 H2AX knockout mice showed cell-autonomous anaemia and erythroid dysplasia, mimicking dyserythropoi

92 ebo-controlled period: one event of aplastic anaemia and five serious adverse events related to raise

93 For children with sickle cell anaemia and high transcranial doppler (TCD) flow velocit

94 Co-trimoxazole prophylaxis reduces anaemia and improves growth in children with HIV, possib

95 ssociated with or causes diseases, including anaemia and iron overload.

96 enrolled 18 adult patients with sickle cell anaemia and leg ulcers into our trial.

97 , and lymphopenia (all for patient number 2; anaemia and lymphopenia were dose-limiting toxicities);

98 Anaemia and malaria are both common in pregnant women in

99 The incidences of grade 3-4 anaemia and neutropenia were similar between the radium-

100 ed to the discontinuation of any study drug--anaemia and neutropenia--were associated with peginterfe

101 ates and severity of adverse events, such as anaemia and rash.

102 ed PUD included smoking, stress, depression, anaemia and social deprivation.

103 The primary outcomes were anaemia and sustained attention.

104 litinib; one patient (1%) reported grade 3-4 anaemia and three patients (4%) reported grade 3-4 throm

105 generally well tolerated, with low rates of anaemia and treatment discontinuation in non-cirrhotic p

106 llent diagnostic accuracy in iron deficiency anaemia and was comparable to conventional serology.

107 high concentration of creatine kinase, mild anaemia), and radiological (thickened calvarium) feature

108 RAB features (hypercalcaemia, renal failure, anaemia, and bone lesions).

109 openia with subcutaneous haemorrhage, severe anaemia, and cardiogenic syncope).

110 LYs) for low birthweight, severe to moderate anaemia, and clinical malaria.

111 uracy of the HCS in primary care to diagnose anaemia, and compared this with clinical assessment.

112 ecommend coeliac serology in iron deficiency anaemia, and duodenal biopsy for those tested positive t

113 tients), increased alanine aminotransferase, anaemia, and fatigue (two [1%] each); for ICC, these inc

114 e groups were neutropenia, thrombocytopenia, anaemia, and febrile neutropenia or infections.

115 rious adverse events were: thrombocytopenia, anaemia, and lymphopenia (all for patient number 2; anae

116 h as clinical malaria, maternal and neonatal anaemia, and miscarriage, all of which increase the over

117 sis, and acute management of iron deficiency anaemia, and outstanding research questions for treatmen

118 od flow, degree of vasculopathy, severity of anaemia, and presence of prior infarct; findings were in

119 is to exclude thrombocytosis and sickle cell anaemia, and serum angiotensin-converting enzyme (SACE)

120 Low haemoglobin concentrations and anaemia are important risk factors for the health and de

121 ow failure diseases such as Diamond-Blackfan anaemia, are not treatable with erythropoietin (Epo), be

122 han 5 x 10(8) cells per L, and in those with anaemia, as any increase in haemoglobin of 20 g/L or hig

123 el therapeutic approach for the treatment of anaemia associated with lower-risk myelodysplastic syndr

124 R] 3.25 [95% CI 2.99-3.54]); AORs for severe anaemia associated with P. falciparum, P. vivax, and P.

125 ects (29.3% of Asian females) presented with anaemia, associated with decreased RBCs volume (MCV) and

126 intervention was observed for prevalence of anaemia at either 12 or 24 months (adjusted risk ratio [

127 Anaemia at grade 3 or higher was slightly more frequent

128 vely recruited patients with iron deficiency anaemia attending for a gastroscopy.

129 Anaemia augmented cardiac mass by 23% without changing b

130 (C=calcium elevation; R=renal impairment; A=anaemia; B=bone involvement) criteria with measurable di

131 a, which occurred in nine (3%) patients, and anaemia, back pain, and pain in extremities, each of whi

132 protocol adherence, separation in degree of anaemia between groups, and non-significant reduction in

133 There was no difference in the prevalence of anaemia between the simeprevir and placebo groups (35 [1

134 ore common in the co-trimoxazole group), and anaemia (both grades equally common in both groups).

135 nductance both increase during chronic fetal anaemia, but the coronary microvascular changes responsi

136 Hydroxyurea treatment reduces haemolysis and anaemia by increasing foetal haemoglobin, which leads to

137 enitors normally seen following induction of anaemia by phenylhydrazine treatment.

138 Fetal anaemia causes cardiac adaptations that have immediate a

139 nts presenting to a separate iron deficiency anaemia clinic were retrospectively reviewed.

140 s in resource-poor settings usually diagnose anaemia clinically, but this is inaccurate.

141 HCS can significantly reduce misdiagnosis of anaemia compared with clinical assessment alone.

142 effective erythropoiesis, chronic haemolytic anaemia, compensatory haemopoietic expansion, hypercoagu

143 Diamond Blackfan anaemia (DBA) is a congenital bone marrow failure syndro

144 (three [7%]) in the bone sarcoma group, and anaemia, decreased lymphocyte count, and prolonged activ

145 f high body lead content, is associated with anaemia, developmental and neurological deficits in chil

146 tious diseases, nutritional deficiencies and anaemia, diabetes, and cardiovascular disease in the bla

147 For severe anaemia, diagnostic accuracy was again higher overall fo

148 Grade 3-4 anaemia did not differ between groups (8.1% vs 8.3%, p=0

149 e case of mice with a non-functional Fanconi anaemia DNA repair pathway, led to a complete collapse o

150 nd efficacy of luspatercept in patients with anaemia due to lower-risk myelodysplastic syndromes.

151 Complications include anaemia due to reduced production of erythropoietin by t

152 of any of these signals ameliorates malarial anaemia during infection in a mouse model.

153 %]), decreased neutrophil count (four [2%]), anaemia, dyspnoea, hyponatraemia, increased alanine amin

154 ive), vomiting (12 [38%] of 32 vs zero), and anaemia (eight [25%] of 32 vs one [20%] of five); genera

155 roup compared with in the placebo group were anaemia (eight [4%] of 207 vs five [5%] of 102 patients)

156 The most common serious adverse events were anaemia (eight [4%]), upper gastrointestinal haemorrhage

157 8%] of 136 patients vs four [3%] of 128) and anaemia (eight [6%] vs one [1%]).

158 ng treatment: two (17%) patients experienced anaemia, eight (67%) neutropenia, and ten (83%) thromboc

159 Repeated sickling and ongoing haemolytic anaemia, even when subclinical, lead to parenchymal inju

160 Fanconi anaemia (FA) is a cancer predisposition syndrome charact

161 Fanconi anaemia (FA) is a genome instability disease caused by d

162 Fanconi anaemia (FA) is a hereditary disease featuring hypersens

163 Fanconi anaemia (FA) is a recessive disorder characterized by ge

164 The Fanconi anaemia (FA) pathway is important for the repair of DNA

165 of pregnancy, maternal conditions including anaemia, fever during labour, and hypertension accounted

166 se events were neutropenia (18 [40%] of 45), anaemia (five [11%]), and peripheral sensory neuropathy

167 group), hypertension (20 [7%] vs two [2%]), anaemia (five [2%] vs six [5%]), and neutropenia (two [1

168 s in the brentuximab vedotin and AVD group), anaemia (five [20%] vs three [12%]), febrile neutropenia

169 %] of 102), thrombocytopenia (six [6%]), and anaemia (five [5%]).

170 We obtained data about haemoglobin and anaemia for children aged 6-59 months and women of child

171 ocardial infarction (five [3%] vs none), and anaemia (four [2%] vs none]).

172 ] of 18 patients), lymphopenia (five [28%]), anaemia (four [22%], and thrombocytopenia in three [17%]

173 (four [25%]), thrombocytopenia (four [25%]), anaemia (four [25%]), fever and infection (four [25%]),

174 al (nine), metabolic (seven), fatigue (six), anaemia (four), pain (four), constitutional (three), and

175 1%], grade 4 11 [10%] in the placebo group), anaemia (grade 3 12 [11%] vs grade 3 16 [15%]), and fati

176 d systemic pathological effects ranging from anaemia, growth stunting, impaired cognition, and decrea

177 Anaemia (haemoglobin <11 g/dL) in late pregnancy was neg

178 , infection (2 [6%]), and one (3%) each with anaemia, haemolysis, fatigue, and a neurological, metabo

179 eived primaquine developed moderately severe anaemia (Hb < 8 g/dL).

180 His mother has Sickle cell anaemia (Hb SS) and his father is a carrier of heterozyg

181 [3%] vs 14 [5%]; HEC-2: 16 [6%] vs 14 [5%]), anaemia (HEC-1: one [<1%] vs one [<1%]; HEC-2: seven [3%

182 In sickle cell anaemia (homozygous HBBE6V; HbSS), plasma EPO is elevate

183 follow-up, 25 (46%) of 58 patients had mild anaemia (ie, not requiring intervention), 22 (45%) had h

184 se events were recorded in 2 of 15 patients (anaemia in 1 patient; pneumonia in 1 patient); all arose

185 pyogenic pneumonia in 26 patients (33%) and anaemia in 15 (19%).

186 toxicities in the 174 treated patients were anaemia in 16 (9%) patients, hyperglycaemia in 18 (10%),

187 273 million (242-304 million) children with anaemia in 2011.

188 lated treatment-emergent adverse events were anaemia in 32 (5%) patients, thrombocytopenia in 15 (2%)

189 ] of 81 patients vs 13 [33%] of 39 patients; anaemia in 32 [40%] vs 11 [28%]; and thrombocytopenia in

190 We also show that PPAR-alpha alleviates anaemia in a mouse model of chronic anaemia.

191 of which were hypertension, neutropenia, and anaemia in both groups, and mild-to-moderate transient i

192 children 0.5-14 y old (primary outcome) and anaemia in children <5 y old (secondary outcome) were co

193 IEZO1 cause an autosomal dominant haemolytic anaemia in humans called dehydrated hereditary stomatocy

194 cyte age and dose-dependent acute haemolytic anaemia in individuals with glucose-6-phosphate dehydrog

195 tolerated and effective for the treatment of anaemia in lower-risk myelodysplastic syndromes and so c

196 e suggests that low maternal iron status and anaemia in pregnancy may increase the risk of childhood

197 24%) patients (grade 4 in one [2%] patient), anaemia in seven (14%) patients, and thrombocytopenia in

198 rmalities in adult patients with sickle cell anaemia in steady state attending the Haematology clinic

199 contribution of malaria to the aetiology of anaemia in this setting.

200 patients and included pyrexia in nine (16%), anaemia in three (5%), confusional state in two (4%), de

201 tients (9%), hyponatraemia in four (7%), and anaemia in three (5%).

202 Many acute and chronic anaemias, including haemolysis, sepsis and genetic bone

203 Anaemia is a major cause of morbidity and mortality in l

204 Sickle cell anaemia is a monogenetic disorder with a high incidence

205 cular flux rate in response to chronic fetal anaemia is consistent with expected reductions in capill

206 clude that the correction of iron deficiency anaemia is in some part due to the treatment of the unde

207 We map Fanconi anaemia-like disease-associated RAD51 mutations, clarify

208 comprise a wide range of diseases including anaemia, malignant blood disorders, and haemorrhagic dis

209 ual changes in microvascular function during anaemia may indicate novel adaptive strategies in the fe

210 on of Postn results in peripheral blood (PB) anaemia, myelomonocytosis and lymphopenia, while the num

211 (P < 0.05) in participants with sickle cell anaemia (n = 27) not receiving monthly blood transfusion

212 e imaging method were applied in sickle cell anaemia (n = 34) and healthy race-matched control (n = 1

213 tenance therapy group were fatigue (n=1) and anaemia (n=1) and in the local consolidative therapy gro

214 ative therapy group were oesophagitis (n=2), anaemia (n=1), pneumothorax (n=1), and abdominal pain (n

215 vents; the most frequent adverse events were anaemia (n=14), weight loss (n=12), and vomiting (n=10).

216 oea (n=11 [5%]) in the pacritinib group, and anaemia (n=16 [15%]), thrombocytopenia (n=12 [11%]), dys

217 Grade 3 adverse events were anaemia (n=2), fatigue (n=1), rash (n=1), and hypothyroi

218 eutropenia (n=6), febrile neutropenia (n=1), anaemia (n=2), lymphopenia (n=1), diarrhoea (n=2), hypoa

219 rade 3-4 adverse events through week 24 were anaemia (n=37 [17%]), thrombocytopenia (n=26 [12%]), and

220 children are frequently admitted with severe anaemia needing an urgent blood transfusion, but blood i

221 -week group; 14 [23%] in the 16-week group), anaemia (nine [15%] in the 12-week group; 12 [20%] in th

222 the most common grade 3 or worse events were anaemia (nine [15%] of 62) and decreased neutrophil coun

223 alignant neoplasm progression (10 [5%]), and anaemia (nine [4%]).

224 ) in those given pembrolizumab 10 mg/kg; and anaemia (nine [5%]), fatigue (eight [5%]), neutropenia (

225 alkaline phosphatase (11 patients, 9%]), and anaemia (nine patients, 7%).

226 ocedures exist for children with sickle cell anaemia, no accepted screening procedures exist for asse

227 e frequently associated with iron deficiency anaemia--notably chronic kidney disease, chronic heart f

228 ive vs one), night sweats (four vs one), and anaemia (one vs three).

229 worse treatment-emergent adverse events were anaemia or decreased haemoglobin (45 [22%] patients), an

230 placebo group, the most common of which were anaemia or decreased haemoglobin concentration (70 [19%]

231 to reduce mortality in children after severe anaemia or severe acute malnutrition.

232 No cases of grade 3-4 anaemia or thrombocytopenia occurred with ruxolitinib; o

233 elofibrosis (with no exclusions for baseline anaemia or thrombocytopenia) were randomly assigned (2:1

234 th at least one of grade 3 thrombocytopenia, anaemia, or bleeding at grade 3 or worse, with palpable

235 , the duodenal histology found no causes for anaemia other than coeliac disease.

236 x functions in the activation of the Fanconi anaemia pathway of the DNA damage response, in regulatin

237 DX2 and functions in parallel to the Fanconi anaemia pathway to promote efficient homologous recombin

238 the intra-S-phase checkpoint and the Fanconi anaemia pathway, which promote ICL incision, translesion

239 ient fibroblasts (PD20) derived from Fanconi anaemia patients displayed reduced spontaneous SCE forma

240 se of alternative donor sources for aplastic anaemia patients remains limited and problematic, but no

241 ltrasonography of 50 consecutive sickle cell anaemia patients were compared with those of 50 age- and

242 lure of the haematopoietic system in Fanconi anaemia patients.

243 enetrant bone marrow failure seen in Fanconi anaemia patients.

244 ique was associated with a reduction in twin anaemia polycythaemia sequence (3% vs 16% for the standa

245 outcome was a composite of incidence of twin anaemia polycythaemia sequence, recurrence of twin-to-tw

246 Anaemia prevalence decreased from 33% (29-37) to 29% (24

247 trations of mean haemoglobin were lowest and anaemia prevalence was highest in south Asia and central

248 rease in mean haemoglobin and a reduction in anaemia prevalence.

249 licated by observations that iron deficiency anaemia protects against falciparum malaria, and that ir

250 Fanconi anaemia proteins can promote stem-cell function, prevent

251 The function of Fanconi anaemia proteins is to maintain genomic stability.

252 SS), plasma EPO is elevated due to hemolytic anaemia-related hypoxia.

253 g with Simtomax in anaemia; 3) whether other anaemia-related pathologies could be missed by this targ

254 e anaemic patients is unlikely to miss other anaemia-related pathologies.

255 splantation in patients with severe aplastic anaemia remains to be established.

256 Because recovery from anaemia requires transient reticulocytosis, our findings

257 Treatment of these anaemias requires a drug that acts at an earlier stage o

258 ve refractory disease, autoimmune haemolytic anaemia requiring treatment, chronic or active infection

259 ll transplantation (HSCT) in severe aplastic anaemia (SAA) have improved steadily over the past decad

260 Sickle cell anaemia (SCA) is associated with structural manifestatio

261 The global burden of sickle cell anaemia (SCA) is set to rise as a consequence of improve

262 e pembrolizumab plus chemotherapy group were anaemia (seven [12%] of 59) and decreased neutrophil cou

263 (26 [53%]), thrombocytopenia (eight [16%]), anaemia (seven [14%]), febrile neutropenia (six [12%]),

264 The most common in the olaparib group were anaemia (seven [4%] patients), abdominal pain (three [2%

265 group vs four [3%] in the placebo group) and anaemia (seven [5%] vs one [<1%]).

266 nts) being pyrexia and autoimmune haemolytic anaemia (seven [7%] each), pneumonia (six [6%]), and feb

267 ] of 75 in the chemotherapy alone group) and anaemia (seven [9%] vs five [7%]).

268 hose assigned single-agent everolimus it was anaemia (six [12%]).

269 requent grade 3 or worse adverse events were anaemia (six [14%]), decreased lymphocyte count (five [1

270 re neutropenia (eight [44%] of 18 patients), anaemia (six [33%]), thrombocytopenia (five [28%]), incr

271 In fetuses, chronic anaemia stimulates cardiac growth; simultaneously, blood

272 improvement from baseline in FACT-An score, anaemia subscale score, and the EQ-5D-5L were reported a

273 her than coeliac disease for iron deficiency anaemia, suggesting that biopsy avoidance in Simtomax ne

274 matological adverse events of any grade were anaemia (ten [14%] of 74 in the ruxolitinib group vs two

275 [1%] in the fulvestrant plus placebo group), anaemia (ten [3%] and three [2%]), and leucopenia (95 [2

276 in group five had a serious adverse event of anaemia, thought to be related to ribavirin treatment.

277 four [4%]), febrile neutropenia (four [4%]), anaemia (three [3%]), and neutropenia (three [3%]) in th

278 such events were pneumonia (three [8%]) and anaemia, thrombocytopenia, abdominal pain, anxiety, and

279 ), hypertension in three patients (10%), and anaemia, thrombocytopenia, and diarrhoea in two patients

280 Anaemia, thrombocytopenia, neutropenia, oesophagitis, di

281 of six predefined factors in the IMDC model (anaemia, thrombocytosis, neutrophilia, Karnofsky perform

282 opists consider duodenal biopsy mandatory in anaemia to exclude other pathologies.

283 l clinical trials in adults with sickle cell anaemia to promote healing of leg ulcers.

284 f SMC and the prevalence of parasitaemia and anaemia, to monitor molecular markers of drug resistance

285 Apart from anaemia, toxicities with olaparib were low grade and man

286 dverse event, with neutropenia (five [56%]), anaemia (two [22%]), and febrile neutropenia (two [22%])

287 The most common adverse events were nausea, anaemia, upper respiratory tract infection, and headache

288 he pooled sensitivity of the HCS to diagnose anaemia was 80% (95% CI 68-88) compared with 52% for cli

289 not noted in those younger than 5 years and anaemia was no more frequent with zidovudine than with t

290 ecreased neutrophil count (n=2); and grade 4 anaemia was reported by one patient.

291 Coma, seizures, tachycardia and anaemia were all significantly associated with mortality

292 titis B or C infection; or active haemolytic anaemia were excluded.

293 ents were balanced between groups except for anaemia, which occurred more frequently in the combined

294 We enrolled children with sickle cell anaemia who were aged 4-16 years and had abnormal TCD fl

295 rolled patients with diagnosis of refractory anaemia with excess blasts (RAEB)-1, RAEB-2, RAEB-t, or

296 -eg, by early identification and reversal of anaemia with haematinics or by reversal of the underlyin

297 ion fraction in individuals with sickle cell anaemia with higher levels of clinical impairment.

298 Health (Bethesda, MD, USA) with sickle cell anaemia with leg ulcers (with a surface area of 2.5-100

299 white blood cell count <13 000/muL), and had anaemia with or without red blood cell transfusion suppo

300 Risk of anaemia within 28 days was lower in patients in the arte